vCologuard® Expansion
3
The information and data presented here was prepared for investors and potential investors. It includes forward-looking information on investigational products in development that are not available for sale in the United States. These include early-stage development products for which the performance characteristics have not yet been established.
Multiple opportunities to expand Cologuard® use
• Evaluating broader US screening populations
– High-risk individuals (20M Americans)
– 40-49 year olds (40M Americans)
• Addressing these markets requires
– Clinical and pharmacoeconomic data
– Guideline committees support
– Regulatory support
Top Related